Thursday 31 Oct, 2024 03:34 PM
Site map | Locate Us | Login
   G E Shipping enters into contract to sell medium range product tanker Jag Padma    Five-Star Business Finance Ltd leads losers in 'A' group    Master Trust Ltd leads losers in 'B' group    Volumes jump at Rainbow Childrens Medicare Ltd counter    FMCG stocks edge lower    Consumer Durables stocks slide    Information Technology shares slide    Shilpa Medicare slips after US FDA issues four form 483 obersvations to Bengaluru facility    LTIMindtree Ltd drops for fifth straight session    Vintage Coffee jumps after early launch of automated packaging line    Automotive Axles slides as Q2 PAT drops 20% to Rs 36 cr    Ajanta Pharma Ltd spurts 2.75%, rises for third straight session    Mankind Pharma Ltd spurts 3.89%    Saregama India Ltd up for third straight session    Prudent Corporate Advisory hit life high as Q2 PAT jumps 69% YoY 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Cipla spurts after USFDA classifies Goa unit as VAI
31-Oct-24   10:59 Hrs IST

The United States Food and Drug Administration (USFDA) conducted routine current Good Manufacturing Practices (cGMP) inspection at Goa manufacturing facility from 10 to 21 June 2024. On conclusion, the company received 6 inspectional observations in Form 483.

The pharma company has now received communication from the USFDA stating the unit as VAI.

According to media reports, 'This VAI is important milestone as it has opened the doors for the company to go ahead and launch Abraxane, a paclitaxel-based chemotherapy drug used to treat cancer with a market size of over $700 million. Currently, only Sandoz has received approval for the same in October 2024.'

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

The pharma major's consolidated net profit jumped 15.18% to Rs 1,302.53 crore on 5.58% rise in total revenue from operations to Rs 7,051.02 crore in Q2 FY25 over Q2 FY24.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 36544286
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd